Ligand id: 9118

Name: TEN-010

Compound class Synthetic organic
TEN-010 (a.k.a. JQ2) is a BET inhibitor. Structurally it is an analogue of (+)-JQ1, with optimised chemical and biological properties. Development of TEN-010 is being progressed by Roche, who acquired the originating biotech firm Tensha Therapeutics. TEN-010 is likely one of the compounds claimed in the Tensha/Bromodomain inhibitors patent WO2016069578 [1].
BET inhibitors bind to the bromodomains of the bromodomain and extra-terminal motif (BET) proteins BRD2, BRD3, BRD4, and BRDT. This mechanism acts to prevent protein-protein interaction between BET proteins and acetylated histones and transcription factors. The action disrupts chromatin remodeling and inhibits expression of some growth-promoting genes which slows proliferation in susceptible tumours.
The chemical structure for TEN-010 has not been disclosed. We will present the structure when available.
Database Links
GtoPdb PubChem SID 315661203